Menopause was associated with greater walking disability and physical fatigue in women with MS, but not increased brain or spinal cord atrophy, according to POINT-MS data presented at #MSToronto2026. ow.ly/a3Mj5100yJH @ECTRIMS @ACTRIMS #MultipleSclerosis #WomensHealth #MSResearch

MRI analysis identified 4 distinct MS subtypes, with cortex-led and deep gray matter/cerebellar-led patterns linked to greater disability and shorter PIRA-free survival, according to data presented at #MSToronto2026. ow.ly/78fm5100ubt @ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Neuroimaging

CD19 CAR T-cell therapy zola-cel showed early disease control in refractory relapsing and progressive MS, with manageable safety in the phase 1 Breakfree-2 study presented at #MSToronto2026. ow.ly/j6Gm5100tsM @ECTRIMS @ACTRIMS #MultipleSclerosis #CARTCellTherapy #MSResearch

Rituximab was noninferior to ocrelizumab for MRI lesion control in newly diagnosed relapsing MS, but infections were more frequent with rituximab, according to phase 3 OVERLORD-MS data at #MSToronto2026. ow.ly/Aphn5100tbp @ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch

Satralizumab was associated with fewer MOGAD relapses (13.2% vs 37.5%) and greater postattack recovery in exploratory phase 3 METEOROID data presented at #MSToronto2026. ow.ly/zPHZ5100t78 @Roche @ECTRIMS @ACTRIMS #MOGAD #Neuroimmunology #Neurology

Fenebrutinib more than halved relapse rates vs teriflunomide and improved MRI and NfL outcomes in a pooled phase 3 FENhance analysis of 1,497 patients with relapsing MS at #MSToronto2026. ow.ly/qOeK5100hJk @Roche @ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch

Early high-efficacy DMT was associated with 36% fewer relapses in MS but did not significantly delay PIRA vs treatment escalation, according to a Danish study presented at #MSToronto2026. ow.ly/uOi75100agV @ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Neurology

MRI activity without relapses was linked to higher risk of PIRA, SPMS, and disability worsening in MS, according to an MSBase study of 19,262 patients presented at #MSToronto2026. ow.ly/eoGK5100b5P @ECTRIMS @ACTRIMS #MultipleSclerosis #MSResearch #Neurology

What increases the risk of late-onset epilepsy? A new JAMA Neurology analysis of 42,257 US adults links #stroke, #diabetes, smoking, kidney disease, and #hypertension to higher epilepsy incidence after age 65. @AmEpilepsySoc @JAMANetwork ow.ly/LEwv50ZZ8L3 #Epilepsy #Neurology

Clene has submitted an @FDA application seeking accelerated approval of CNM-Au8 as treatment for those diagnosed with amyotrophic lateral sclerosis (ALS), citing neurofilament light chain biomarker data. ow.ly/GMzp50ZZ8y6 @alsassociation #ALS #CNMAu8 #Neurology #Neuromuscular

Adults taking enzyme-inducing antiseizure medications had 51% higher adjusted odds of osteoporosis or osteopenia, yet only 20.7% had documented vitamin D supplementation, according to research presented at @ANAneurology #ANA2026. ow.ly/HyP050ZZ8tM #Epilepsy #BoneHealth #Neurology

Investigational adrabetadex was linked to preservation of neurological function for over 10 years in 2 sisters with infantile-onset Niemann-Pick disease type C. New data presented at @ChildNeuroSoc #CNSAM. ow.ly/4zLk50ZZ8oZ #NiemannPick #RareDisease #PediatricNeurology

Pregnancy can serve as a #neurovascular stress test—and a window for #StrokePrevention. Rodica Di Lorenzo, MD, PhD, and Katherine Singh, MD, make the case for coordinated maternal neurovascular care. ow.ly/W47x50ZYIhr @ClevelandClinic #MaternalStroke #WomensHealth #VascularNeurology @American_Stroke

Adolescents with #GeneralizedMyastheniaGravis showed sustained improvements in daily function and muscle strength through week 108 of treatment with #Imaavy. ow.ly/h1jq50ZYIfj #nipocalimab #gMG #Myasthenia @MyastheniaOrg @AANEMorg @JNJNews

The FDA has approved a once-daily Zilbrysq (zilucoplan) autoinjector for adults with AChR antibody-positive generalized myasthenia gravis, expanding self-administration options. ow.ly/iKri50ZYAxw @ucb_news @MyastheniaOrg @AANmember #MyastheniaGravis #gMG #Neurology #FDAApproval

What can #wearable data tell clinicians about #Parkinson's between office visits? In our current issue, Siegfried Hirczy, MD, and Ruth B. Schneider, MD provide a practical framework for evaluating wearable technology in clinical care. ow.ly/VmyG50ZXMjU @URMC_Neurology @movedisorder @MichaelJFoxOrg @ParkinsonDotOrg @AANmember

A diffusion MRI–based measure of cortical microstructure corresponded with the distribution of autopsy-confirmed pathology in people with #frontotemporal lobar degeneration. ow.ly/SePv50ZXM93 @AFTDHope #FTD @AANmember @alzassociation

The @US_FDA has accepted the New Drug Application for #fenebrutinib with priority review for both relapsing #multiple_sclerosis and primary progressive #MS. ow.ly/WpI650ZXpXR @AANmember @mssociety @ACTRIMS @genentech

Exposure to anti-#CGRP monoclonal antibodies in early #pregnancy was associated with a 42% higher adjusted risk of spontaneous abortion among individuals with #migraine. ow.ly/oO9x50ZX1Qe @ahsheadache @amfmigraine @NHF @JAMANeuro

Where does #magnetoencephalography fit in presurgical #Epilepsy evaluation? Abbas Babajani-Feremi, PhD, and Giridhar P Kalamangalam, MD, DPhil, examine how #MEG can refine localization and guide invasive monitoring and surgical planning. ow.ly/tpCK50ZWuYb @EpilepsyFdn @AANmember @AmEpilepsySoc @UFNews